Amgen and Teva launched Stelara biosimilars in the US.

1 report, 1 independent Updated Jul 24

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Johnson & Johnson Amgen Teva Pharmaceutical Industries Ltd.

Keep exploring

Part of

J&J faces patent challenges and competitive pressure from biosimilars launched by Amgen and Teva, compounded by new price setting requirements under the Inflation Reduction Act. All 1 developments

Within Johnson & Johnson, Eli Lilly, Sandoz, and Teva are key market players, with a news release issued from Austin, TX.

The entities involved

Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04
Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
- Teva Pharmaceutical Industries Ltd. is being investigated by the Competition Authority regarding generic competition practices.Mon 13:16

Coverage

Newest first; wire copies grouped

Jul 24ZacksJ&J Innovative Medicine Unit Shines Again in Q2: Will This Continue? Johnson & Johnson’s JNJ Innovative Medicine segment markets several multi-million-dollar drugs that cover a broad range of areas,